Biotech
-
Formation Bio Licenses Phase 1-Ready CNS Penetrant TYK2 Inhibitor from Lynk Pharmaceuticals
The following excerpt was taken from PR Newswire– continue reading here. NEW YORK, Dec. 10, 2025 /PRNewswire/ — Formation Bio and Lynk Pharmaceuticals today announced Formation Bio’s acquisition of worldwide rights, excluding Greater China, to LNK01006, a next generation central nervous system (CNS)–penetrant highly selective TYK2 inhibitor. The asset will be developed within Formation’s newly formed subsidiary Bleecker Bio. LNK01006